[Federal Register: July 14, 2003 (Volume 68, Number 134)]
[Notices]
[Page 41594-41595]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14jy03-72]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Methods and Devices for
Intramuscular Stimulation of Upper Airway and Swallowing Muscle Groups
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR
[[Page 41595]]
404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive worldwide license to practice the invention embodied in:
E-181-2002; U.S. Provisional Patent Application 60/413,773 entitled
``Methods and Devices for Intramuscular Stimulation of Upper Airway and
Swallowing Muscle Groups,'' to the Alfred Mann Foundation, a non-profit
organization having a place of business in Valencia, California. The
United States of America is an assignee to the patent rights of these
inventions.
The contemplated exclusive license may be limited to the use of the
Alfred Mann Foundation BION[reg] system for treating
dysphagia and dysphonia.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
September 12, 2003 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Michael A. Shmilovich, J.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 435-5019; Facsimile: (301) 402-0220; e-
mail: shmilovichm@od.nih.gov. A signed Confidential Disclosure
Agreement will be required to receive copies of the patent application.
SUPPLEMENTARY INFORMATION: The patent application covers devices and
methods for intramuscular stimulation (stimulation of the geniohyoid,
mylohyoid, and thyrohyoid muscles) in patients with neuromuscular
disorders. The invention provides autonomous control of both
hyolaryngeal elevations, anterior hyoid motion and opening of the upper
esophageal sphincter for swallowing, vocalization and speech.
Primarily, the technology allows self-stimulation of swallowing and can
return oral feeding to dysphagia patients. Electrodes are attached to
the appropriate musculature of the neck and an electrode stimulator or
subcutaneous signal generator modulates electrostatic pulses through
the electrodes that cause the attached muscles to contract simulating
natural swallowing or vocalization depending on placement.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 7, 2003.
Steven M. Ferguson,
Acting Director, Division of Technology development and Transfer,
Office of Technology Transfer.
[FR Doc. 03-17650 Filed 7-11-03; 8:45 am]
BILLING CODE 4140-01-P